name

õ¿¬¹°¿¡¼­ ±â´É¼º¼ÒÀ縦 °³¹ßÇÏ¿© »óÇ°È­ÇÏ´Â Àü¹®Áö½Ä°ú ±â¼ú·ÂÀ¸·Î õ¿¬¹ÙÀÌ¿À»ê¾÷ÀÇ ¹Ì·¡¸¦ °³Ã´ÇØ ³ª¾Æ°©´Ï´Ù
NET 1701
Ultimate men¡¯s prostate and urinary support
NET 1701

NET 1701Àº ¶ãº¸¸®¼ö ¹× ¹é¼ö¿À ÁÖÁ¤ÃßÃâ¹°À» À¯È¿¼ººÐÀ¸·Î ÇÏ´Â ³²¼º Àü¸³¼± °Ç°­À» À§ÇÑ Æ¯Çã Á¶¼º¹°ÀÔ´Ï´Ù.
Àü¸³¼± ¼ºÀå¿¡ °ü¿©ÇÏ´Â Àü¸³¼± ƯÀÌÈ¿¼Ò 5¥á-reductase¸¦ ¾ïÁ¦ÇØ Àü¸³¼± ¼ºÀåÀ» ¿¹¹æ ¹× °³¼±Çϴµ¥ µµ¿òÀ» µå¸®¸ç
Å×½ºÅ佺Å×·Ð Áõ°¡·Î ¼º±â´É °ü·Ã ºÎÀÛ¿ë ¾øÀÌ ¾ÈÀüÇÏ°Ô ¼·ÃëÇÒ ¼ö ÀÖ½À´Ï´Ù.

Exclusivity

±¹°¡ µî·Ï¹øÈ£ ƯÇã ¸íĪ
´ëÇѹα¹ 10-2195505 ¶ãº¸¸®¼ö³ª¹« ¿­¸Å ÃßÃâ¹°À» À¯È¿¼ººÐÀ¸·Î ÇÔÀ¯ÇÏ´Â
Àü¸³¼±ºñ´ëÁõ ¿¹¹æ ¹× Ä¡·á¿ë Á¶¼º¹°
(Pharmaceutical composition containing Elaeagnus multiflora Thunb.
extract for treating and preventing benign prostatic hyperplasia)

Mechanism of Action

5¥á-Reductase ¾ïÁ¦¸¦ ÅëÇÑ Àü¸³¼± ºñ´ë ¾ïÁ¦

Àü¸³¼±¾Ï LNCaP ¼¼Æ÷ÀÇ ´Ü¹éÁú ¹ßÇö È®ÀÎ
Àü¸³¼± ƯÀÌÈ¿¼Ò(5¥á-reductase), ¾Èµå·Î°Õ¼ö¿ëü(AR),
Àü¸³¼± ƯÀÌÇ׿ø(PSA) ´Ü¹éÁú ¹ßÇö ¾ïÁ¦
4ÁÖ°£ Åõ¿©, testosterone propionate Àü¸³¼± ºñ´ëÁõ À¯µµ
in vivo test °á°ú
5¥á-reductase À¯ÀüÀÚ SRD5A2 ¹ßÇö ¾ïÁ¦
Àü¸³¼± ƯÀÌÇ׿ø PSA À¯ÀüÀÚ ¹ßÇö ¾ïÁ¦
Àü¸³¼± ¹«°Ô °¨¼Ò
Àü¸³¼± Áö¼ö °³¼±
TM3 Leydig cell °íȯ¼¼Æ÷
Å×½ºÅ佺Å×·Ð Áõ°¡

Clinical trial

ONGOING
to be completed in 2024

Recommended dosage

500 mg/day